Mathieu Wémeau, Jordan Gauthier, Xavier Leleu, Ibrahim Yakoub-Agha
CHRU, hôpital Huriez, Lille Cedex, France.
Bulletin du cancer 2011 AugIMiDs belong to a new pharmalogical class, whose principal therapeutic agents are the thalidomide and the lenalidomide. They have immunomodulatory and antiangiogenic properties, as well as a direct effect on tumor cells. Thalidomide and lenalidomide were first approved for multiple myeloma, and in 5q-myelodysplastic syndrome for lenalidomide. Several studies have shown the efficacy of these drugs in others hematologic malignancies. A third component has been developed, the pomalidomide, which may be more effective in certain indications. Here we present an overview of IMiDs in hematology, including mechanisms of action and known significant side effects.
Mathieu Wémeau, Jordan Gauthier, Xavier Leleu, Ibrahim Yakoub-Agha. IMiDs in hematology]. Bulletin du cancer. 2011 Aug;98(8):879-87
PMID: 21827980
View Full Text